New therapeutic modalities in the treatment of graft-versus-host disease

Critical Reviews in Oncology/Hematology

Volumn 38, Issue 2, 2001, Pages 129-138

  Basara, N ^a   Kiehl, M G ^a   Fauser, A A ^a  

^a Clinic for Bone Marrow Transplantation and Hematology/Oncology   (Germany)

Author keywords

GvHD; Haemopoietic stem cell transplantation; Mycophenolate mofetil

Indexed keywords

BUSULFAN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THALIDOMIDE;

ACUTE DISEASE; CHRONIC DISEASE; DEPLETION; DISEASE SEVERITY; GENETIC MANIPULATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; RELAPSE; REVIEW; SUICIDE GENE; T LYMPHOCYTE; TRANSPLANTATION;

COMBINED MODALITY THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 0035058630     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00123-2     Document Type: Review

References (84)

1. Pathophysiology and treatment of graft-versus-host disease
2. Cytokin disregulation and acute graft-versus-host-disease
3. The role of cytokines in graft-versus-host reactions and disease
4. The pathophysiology of graft-versus-host-disease
5. Effect of total body irradiation, busulfyn-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H2-incompatible transplanted SCID mice
6. Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
7. Cytokine induced differentiation of precursor mouse CD8+ T-cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines
8. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection
9. Chronic graft-versus-host-disease
10. Acute and chronic graft-versus-host disease
11. Specificity of effector T-lymphocytes in autologous graft-versus-host disease. Role of major histocompatibility complex class II invariant chain peptide
12. Risk factors for acute graft-host-disease in 291 consecutive HLA-identical bone marrow transplant recipients
13. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors
14. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
15. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host-disease prophylaxis regimen of cyclosporine, methotrexate and prednisone
16. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host-disease after bone marrow transplantation
17. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation
18. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation
19. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum
20. Risk factors for acute graft-versus-host disease
21. Bone marrow transplantation in patients aged 45 years and older
22. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors
23. FK506 in combination with methotrexate for the prevention of graft-versus-host-disease after marrow transplantation from matched unrelated donors
24. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
25. Meeting report. Consensus conference on acute GVHD grading
26. Cutaneous manifestations of graft-versus-host disease
27. Graft-versus-host disease
28. A chronic pulmonary syndrome associated with graft-versus-host-disease after allogeneic marrow transplantation
29. Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host-disease
30. Marrow transplantation from related donors other than HLA-identical siblings
31. Unrelated donor bone marrow transplantation: Influence of HLA-A and -B incompatibility on outcome
32. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
33. Definition of HLA-DQ as a transplantation antigen
34. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
35. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program
36. Cyclosporine A to prevent graft-versus-host-disease in man after allogeneic bone marrow transplantation
37. Cyclosporine as prophylaxis for graft versus host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia
38. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host-disease after histocompatible sibling allogeneic bone marrow transplantation
39. Tacrolimus (FK506) alone or in combination with MTX or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single center study
40. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
41. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants
42. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation
43. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors
44. Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors
45. Selective depletion of CD8+ T-lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation
46. Selective depletion of bone marrow T-lymphocytes with anti-CD5 monoclonal antibody: effective prophylaxis for graft versus-host disease in patients with hematologic malignancies
47. Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomised trial in patients with leukemia treated with HLA-identical sibling marrow grafts
48. Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients
49. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European group for blood and marrow transplantation (EBMT). Chronic leukaemia working party of the EBMT
50. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention
51. Early treatment of acute graft-versus-host-disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation
52. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation
53. Treatment of graft versus host disease in human allogeneic human marrow graft recipients: a randomized trial comparing antithymoycte globulin and corticosteroids
54. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin 2 receptor monoclonal antibody. A multicenter phase III study
55. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
56. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
57. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients
58. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients
59. The efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipients
60. Outpatient PBSC allografts using immunosuppression with low dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant
61. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin
62. Phase I/II evaluation of intravenous tresperismus (LF 08-0299) and methylprednisolone as first line therapy for acute graft-versus-host-disease
63. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin 2 receptor monoclonal antibody. A multicenter phase III study
64. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment
65. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT
66. OKT3 for steroid-resistant acute GVHD: a three-center experience
67. Mycophenolate mofetil (MMF) as secondary treatment modality in acute graft-versus-host disease (AGVHD) after allogeneic BMT/PBSCT - results of a phase II clinical trial
68. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10)
69. Daclizumab, a humanizes anti-interleukin-2 receptor alpha chain antibody for treatment of acute graft-versus-host-disease
70. Treatment of steroid-resistant acute & chronic GVHD with a monoclonal interleukin-2 receptor antagonist (Daclizumab)
71. A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease
72. The management of chronic graft-versus-host-disease
73. Thalidomide for the treatment of chronic graft-versus-host disease
74. Thalidomide as salvage therapy for chronic graft-versus-host disease
75. Treatment of chronic graft-versus-host-disease with clofazimine
76. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients
77. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease
78. Low-dose (one gray) total-lymphoid irradiation for extensive drug resistant chronic graft-versus-host disease
79. Salvage therapy for refractory chronic graft-versus-host-disease with mycophenolate mofetil and tacrolimus
80. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia